20 withdrawn. 20 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Withdrawn 20 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype Exa-cel - Sickle Cell Disease | Phase 3 | Withdrawn | Vertex Pharmaceuticals Incorporated | 2027-07-31 | 2026-03-25 | |
| Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease vadadustat - Anemia of Chronic Kidney Disease | Phase 3 | Withdrawn | Akebia Therapeutics | 2025-01-01 | 2025-10-01 | |
| Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease ferric citrate, standard of care - Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease | Phase 3 | Withdrawn | Keryx Biopharmaceuticals | 2025-01-01 | 2025-11-20 | |
| Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents Vadadustat - Anemia of Chronic Kidney Disease | Phase 3 | Withdrawn | Akebia Therapeutics | 2025-01-01 | 2025-10-01 | |
| Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD Roxadustat - Anemia Associated With Chronic Kidney Disease | Phase 3 | Withdrawn | Kyntra Bio | 2022-05-23 | 2022-07-05 | |
| Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Hetrombopag - Aplastic Anemia, Drug Effect | Phase 2 / Phase 3 | Withdrawn | Peking Union Medical College Hospital | 2021-10-01 | 2026-06-08 | |
| Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease. Brilinta, Placebo - Sickle Cell Disease | Phase 3 | Withdrawn | AstraZeneca | 2020-06-30 | 2020-07-15 | |
| Polyglucoferron Compared to i.v. Ferric Carboxymaltose and Oral Iron Substitution in Preoperative Treatment of Iron Deficiency Anaemia in Patients Polyglucoferron, Ferric carboxymaltose, Ferrous Sulfate - Iron Deficiency Anemia | Phase 3 | Withdrawn | Dr. Frank Behrens | 2020-05-15 | 2024-08-28 | |
| Ketamine Sickle Cell Disease Ketamine - SC Disease, Pain, Chronic | Phase 3 | Withdrawn | University of South Florida | 2018-09-01 | 2018-09-26 | |
| Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Vadadustat, Darbepoetin alfa - Anemia, Dialysis-Dependent Chronic Kidney Disease | Phase 3 | Withdrawn | Akebia Therapeutics | 2017-08-01 | 2018-11-05 | |
| Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly prednisone induction - chloroquine, Chloroquine - Hyper-reactive Malarial Splenomegaly, Malaria | Phase 3 | Withdrawn | Lihir Medical Centre | 2016-01-01 | 2015-11-13 | |
| Red Blood Cell Precursor Formulation to Determine Increased Production RBCPF - Anemia | Phase 2 / Phase 3 | Withdrawn | Targeted Medical Pharma | 2012-10-01 | 2016-05-05 | |
| The Plasma Large-Volume Exchange RCT Plasma Exchange - Purpura, Thrombotic Thrombocytopenic, Hemolytic Uremic Syndrome | Phase 3 | Withdrawn | London Health Sciences Centre | 2012-04-01 | 2013-04-17 | |
| Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects oxymorphone IR - Chronic Pain | Phase 3 | Withdrawn | Endo USA Inc., a Keenova Therapeutics Company | 2010-10-01 | 2012-08-17 | |
| Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP) HX575 solution for s.c. administration - Anemia, Chronic Renal Insufficiency | Phase 3 | Withdrawn | Sandoz | 2009-04-01 | 2015-06-02 | |
| Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease Darbepoetin alfa - Anemia, Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2008-11-01 | 2013-10-30 | |
| Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease iron sucrose - Chronic Kidney Disease, Chronic Heart Failure | Phase 3 | Withdrawn | Anemia Working Group Romania | 2008-01-01 | 2017-12-22 | |
| A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia. methoxy polyethylene glycol-epoetin beta - Anemia | Phase 3 | Withdrawn | Hoffmann-La Roche | 2007-10-01 | 2016-08-24 | |
| A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery. epoetin alfa - Anemia, Blood Transfusion | Phase 3 | Withdrawn | Janssen-Ortho Inc., Canada | 1996-05-01 | 2016-09-20 | |
| A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo Iron isomaltoside 1000, Natrium Chloride 0,9% - Iron Deficiency Anemia | Phase 3 | Withdrawn | Pharmacosmos A/S | 2016-09-28 |
Renal Insufficiency, Chronic (5) · Anemia, Iron-Deficiency (3) · Anemia, Sickle Cell (3) · Chronic Pain (2) · Kidney Diseases (2) · Acute Chest Syndrome (1) · Anemia, Aplastic (1) · Arthritis, Juvenile (1) · Hemoglobin SC Disease (1) · Hemolytic-Uremic Syndrome (1) · Iron Deficiencies (1) · Malaria (1) · Neoplasms (1) · Pulmonary Disease, Chronic Obstructive (1)
Hematologic Diseases (20) · Hemic and Lymphatic Diseases (20) · Pathological Conditions, Signs and Symptoms (9) · Pathologic Processes (7) · Chronic Disease (6) · Disease Attributes (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Male Urogenital Diseases (6) · Urogenital Diseases (6) · Urologic Diseases (6) · Anemia, Hemolytic (5) · Renal Insufficiency (5) · Anemia, Hemolytic, Congenital (4)
vadadustat (3) · Darbepoetin alfa (2) · Chloroquine (1) · Epoetin Alfa (1) · Ferric Oxide, Saccharated (1) · Ketamine (1) · Plasma Exchange (1) · Prednisone (1) · Standard of Care (1) · Ticagrelor (1) · chloroquine diphosphate (1) · continuous erythropoietin receptor activator (1) · exagamglogene autotemcel (1) · ferric carboxymaltose (1) · ferric citrate (1)
Akebia Therapeutics (3) · Anemia Working Group Romania (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Dr. Frank Behrens (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Hoffmann-La Roche (1) · Janssen-Ortho Inc., Canada (1) · Keryx Biopharmaceuticals (1) · Kyntra Bio (1) · Lihir Medical Centre (1) · London Health Sciences Centre (1) · Peking Union Medical College Hospital (1) · Pharmacosmos A/S (1) · Sandoz (1)
United States (6) · France (2) · Germany (2) · Romania (2) · Bulgaria (1) · Canada (1) · China (1) · Denmark (1) · Papua New Guinea (1) · Spain (1)
Anders Berggren, MD, PhD (1) · Bing Han, Master (1) · Enrico Camporesi, MD (1) · Gabriel Mircescu, Professor (1) · Kai Zacharowski, Prof. MD (1) · Karsten Roth (1) · Laurent Savale, MD (1) · Lawrence May, MD (1) · Liliana Garneata, MD, PhD (1) · Oriol Mitja, PhD (1) · Tiberiu Nanea, Professor (1)
2023 (1)